Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,912
  • Shares Outstanding, K 186,894
  • Annual Sales, $ 7,770 K
  • Annual Income, $ -116,660 K
  • EBIT $ -142 M
  • EBITDA $ -137 M
  • 60-Month Beta 2.23
  • Price/Sales 4.56
  • Price/Cash Flow N/A
  • Price/Book 0.40
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -52.74
  • Most Recent Earnings $-0.23 on 11/12/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.84
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -3.45
  • Prior Year -27.48
  • Growth Rate Est. (year over year) +93.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1264 +46.36%
on 11/18/24
0.2763 -33.04%
on 11/20/24
+0.0457 (+32.81%)
since 11/01/24
3-Month
0.1180 +56.78%
on 10/03/24
0.2763 -33.04%
on 11/20/24
+0.0171 (+10.18%)
since 09/03/24
52-Week
0.1180 +56.78%
on 10/03/24
22.1376 -99.16%
on 12/19/23
-16.7718 (-98.91%)
since 12/01/23

Most Recent Stories

More News
Tonix Pharmaceuticals Announces Appointment of New Executives to Support Upcoming TNX-102 SL Launch for Fibromyalgia Management

Tonix Pharmaceuticals hires Bradley Raudabaugh and Errol Gould to enhance marketing and medical affairs ahead of TNX-102 SL FDA review.Quiver AI SummaryTonix Pharmaceuticals has announced the appointment...

TNXP : 0.1850 (-0.96%)
Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires

TNXP : 0.1850 (-0.96%)
Tonix Pharmaceuticals to Present at NobleCon20 Annual Emerging Growth Equity Conference

Tonix Pharmaceuticals will present at NobleCon20 and conduct investor meetings in December 2024 in Boca Raton, Florida.Quiver AI SummaryTonix Pharmaceuticals Holding Corp. announced that Jessica Morris,...

TNXP : 0.1850 (-0.96%)
Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference

TNXP : 0.1850 (-0.96%)
Tonix Pharmaceuticals Reports Positive Phase 3 Results for TNX-102 SL in Fibromyalgia, Submits NDA to FDA

Tonix Pharmaceuticals presented Phase 3 RESILIENT study results for TNX-102 SL, showing significant improvements in fibromyalgia symptoms. NDA submitted to FDA.Quiver AI SummaryTonix Pharmaceuticals presented...

TNXP : 0.1850 (-0.96%)
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual

TNXP : 0.1850 (-0.96%)
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

TNXP : 0.1850 (-0.96%)
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

TNXP : 0.1850 (-0.96%)
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals

TNXP : 0.1850 (-0.96%)
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights

TNXP : 0.1850 (-0.96%)

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

3rd Resistance Point 0.2096
2nd Resistance Point 0.2042
1st Resistance Point 0.1946
Last Price 0.1850
1st Support Level 0.1796
2nd Support Level 0.1742
3rd Support Level 0.1646

See More

52-Week High 22.1376
Fibonacci 61.8% 13.7261
Fibonacci 50% 11.1278
Fibonacci 38.2% 8.5295
Last Price 0.1850
52-Week Low 0.1180

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar